Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 3/20 | 0.34 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.33 |
| ▸ | POLRMT | O00411 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10149552 | 0.93 | CYP3A4 (0.33) | BTN3A1TMPRSS2POLRMTCYP3A4CYP2C9 | |
| SCHEMBL10142379 | 0.90 | BTN3A1 (0.34) | BTN3A1CYP3A4CYP2C9 | |
| SCHEMBL10142732 | 0.90 | RIPK1 (0.32) | BTN3A1 | |
| SCHEMBL15340432 | 0.90 | CYP3A4 (0.38) | BTN3A1CYP3A4CYP2C9 | |
| SCHEMBL10142570 | 0.90 | CYP3A4 (0.38) | BTN3A1CYP3A4CYP2C9 | |
| SCHEMBL17722669 | 0.88 | TMPRSS2 (0.43) | BTN3A1TMPRSS2POLRMT | |
| SCHEMBL10142564 | 0.88 | CYP3A4 (0.39) | BTN3A1TMPRSS2CYP3A4CYP2C9 | |
| SCHEMBL15340437 | 0.88 | CYP3A4 (0.39) | BTN3A1TMPRSS2CYP3A4CYP2C9 | |
| SCHEMBL10142516 | 0.87 | CYP3A4 (0.45) | BTN3A1TMPRSS2CYP3A4CYP2C9 | |
| SCHEMBL10120472 | 0.87 | CYP3A4 (0.45) | BTN3A1TMPRSS2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2576534-B1 | 1'-SUBSTITUTED-CARBA-NUCLEOSIDE PRODRUGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES INC (US) | 2014-03-19 | — | — | EP | disclosed |
| US-8415308-B2 | 1′-substituted-carba-nucleoside prodrugs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415308-B2 | 1′-substituted-carba-nucleoside prodrugs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20120020921-A1 | 1'-SUBSTITUTED-CARBA-NUCLEOSIDE PRODRUGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120020921-A1 | 1'-SUBSTITUTED-CARBA-NUCLEOSIDE PRODRUGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120020921-A1 | 1'-SUBSTITUTED-CARBA-NUCLEOSIDE PRODRUGS FOR ANTIVIRAL TREATMENT | PNP, TYMP, MTAP | BTN3A1 3871/4885TMPRSS2 2225/4885POLRMT 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.